No link found between bladder cancer, use of pioglitazone or rosiglitazone, Avandia — ScienceDaily
Bladder cancer is the ninth most common cancer in the world, with 430,000 new cases diagnosed in 2012. Europe and North America have the highest incidence of bladder cancer, with an even higher incidence in people with diabetes. Bladder tumours overexpress a natural part of the cell machinery, a transcription factor in the cell nucleus known as ‘peroxisome proliferator-activated receptor gamma’ (or PPARγ) that is found in the urothelium (the lining of the urinary tract). Both pioglitazone and rosiglitazone are part of the thiazolidinediones (TZDs) class of drugs, which act as PPARγ agonists, meaning they induce the same action as PPARγ…